Gene Biotherapeutics, Inc. (CRXM)
USD 0.0
(9900.0%)
USD 0.0
(9900.0%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2022 | - USD | 0.0% |
| 2021 | - USD | 100.0% |
| 2020 | -1.26 Million USD | -50.8% |
| 2019 | -837 Thousand USD | -63.09% |
| 2018 | -513.23 Thousand USD | 75.28% |
| 2017 | -2.07 Million USD | 26.92% |
| 2016 | -2.84 Million USD | 8.8% |
| 2015 | -3.11 Million USD | 12.9% |
| 2014 | -3.57 Million USD | 48.22% |
| 2013 | -6.9 Million USD | 17.68% |
| 2012 | -8.38 Million USD | -13.1% |
| 2011 | -7.41 Million USD | -9.57% |
| 2010 | -6.76 Million USD | 22.3% |
| 2009 | -8.71 Million USD | 63.27% |
| 2008 | -23.71 Million USD | 8.08% |
| 2007 | -25.8 Million USD | -33.64% |
| 2006 | -19.3 Million USD | -245.53% |
| 2005 | -5.58 Million USD | -1496.51% |
| 2004 | -350.03 Thousand USD | 15.65% |
| 2003 | -414.97 Thousand USD | 91.53% |
| 2002 | -4.89 Million USD | -85102.0% |
| 2001 | -5750.00 USD | 99.97% |
| 2000 | -18.53 Million USD | -2169.85% |
| 1999 | -816.59 Thousand USD | 82.27% |
| 1998 | -4.6 Million USD | 14.97% |
| 1997 | -5.41 Million USD | -4.19% |
| 1996 | -5.19 Million USD | 18.75% |
| 1995 | -6.39 Million USD | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2022 FY | - USD | 0.0% |
| 2021 FY | - USD | 100.0% |
| 2020 Q1 | -152.88 Thousand USD | 13.97% |
| 2020 FY | -1.26 Million USD | -50.8% |
| 2020 Q3 | -388.69 Thousand USD | -208.78% |
| 2020 Q4 | -1.07 Million USD | -177.32% |
| 2020 Q2 | 357.34 Thousand USD | 333.74% |
| 2019 FY | -837 Thousand USD | -63.09% |
| 2019 Q1 | -242.97 Thousand USD | 0.0% |
| 2019 Q2 | -240.82 Thousand USD | 0.88% |
| 2019 Q3 | -175.49 Thousand USD | 27.13% |
| 2019 Q4 | -177.7 Thousand USD | -1.26% |
| 2018 FY | -513.23 Thousand USD | 75.28% |
| 2017 Q1 | -651.98 Thousand USD | 17.23% |
| 2017 FY | -2.07 Million USD | 26.92% |
| 2016 Q3 | -1.01 Million USD | -66.46% |
| 2016 Q1 | -424 Thousand USD | -137.59% |
| 2016 FY | -2.84 Million USD | 8.8% |
| 2016 Q4 | -787.71 Thousand USD | 22.46% |
| 2016 Q2 | -610.32 Thousand USD | -43.94% |
| 2015 Q4 | -178.46 Thousand USD | 85.0% |
| 2015 FY | -3.11 Million USD | 12.9% |
| 2015 Q1 | -608.25 Thousand USD | -24.81% |
| 2015 Q2 | -1.43 Million USD | -136.48% |
| 2015 Q3 | -1.18 Million USD | 17.28% |
| 2014 Q1 | -1.43 Million USD | -89.63% |
| 2014 Q2 | -956.32 Thousand USD | 33.52% |
| 2014 FY | -3.57 Million USD | 48.22% |
| 2014 Q3 | -713.2 Thousand USD | 25.42% |
| 2014 Q4 | -487.33 Thousand USD | 31.67% |
| 2013 Q3 | -1.76 Million USD | 16.44% |
| 2013 FY | -6.9 Million USD | 17.68% |
| 2013 Q1 | -2.26 Million USD | -15.54% |
| 2013 Q2 | -2.11 Million USD | 6.4% |
| 2013 Q4 | -758.56 Thousand USD | 57.12% |
| 2012 Q4 | -1.95 Million USD | -3.24% |
| 2012 FY | -8.38 Million USD | -13.1% |
| 2012 Q3 | -1.89 Million USD | -1.03% |
| 2012 Q2 | -1.87 Million USD | 29.42% |
| 2012 Q1 | -2.65 Million USD | -39.83% |
| 2011 Q2 | -1.97 Million USD | -11.12% |
| 2011 Q1 | -1.77 Million USD | -18.95% |
| 2011 Q4 | -1.9 Million USD | -8.11% |
| 2011 FY | -7.41 Million USD | -9.57% |
| 2011 Q3 | -1.75 Million USD | 11.04% |
| 2010 Q3 | -1.82 Million USD | 7.66% |
| 2010 FY | -6.76 Million USD | 22.3% |
| 2010 Q1 | -1.48 Million USD | 8.99% |
| 2010 Q2 | -1.97 Million USD | -33.2% |
| 2010 Q4 | -1.49 Million USD | 17.85% |
| 2009 Q2 | -2.32 Million USD | 33.4% |
| 2009 Q3 | -2.25 Million USD | 3.11% |
| 2009 Q4 | -1.62 Million USD | 27.71% |
| 2009 Q1 | -3.48 Million USD | 22.99% |
| 2009 FY | -8.71 Million USD | 63.27% |
| 2008 FY | -23.71 Million USD | 8.08% |
| 2008 Q2 | -6.55 Million USD | 1.94% |
| 2008 Q3 | -5.96 Million USD | 9.01% |
| 2008 Q4 | -4.52 Million USD | 24.03% |
| 2008 Q1 | -6.68 Million USD | 5.02% |
| 2007 Q4 | -7.03 Million USD | -13.18% |
| 2007 Q3 | -6.21 Million USD | 6.26% |
| 2007 Q2 | -6.62 Million USD | -11.87% |
| 2007 FY | -25.8 Million USD | -33.64% |
| 2007 Q1 | -5.92 Million USD | 17.13% |
| 2006 FY | -19.3 Million USD | -245.53% |
| 2006 Q4 | -7.15 Million USD | -27.73% |
| 2006 Q3 | -5.59 Million USD | -47.95% |
| 2006 Q2 | -3.78 Million USD | -37.81% |
| 2006 Q1 | -2.74 Million USD | 0.0% |
| 2005 Q2 | -35.53 Thousand USD | -7.29% |
| 2005 FY | -5.58 Million USD | -1496.51% |
| 2005 Q3 | -114.12 Thousand USD | -221.19% |
| 2005 Q1 | -33.11 Thousand USD | 50.84% |
| 2004 Q3 | -79.33 Thousand USD | 6.76% |
| 2004 Q4 | -67.36 Thousand USD | 15.1% |
| 2004 Q2 | -85.08 Thousand USD | -4.01% |
| 2004 FY | -350.03 Thousand USD | 15.65% |
| 2004 Q1 | -81.8 Thousand USD | 21.18% |
| 2003 FY | -414.97 Thousand USD | 91.53% |
| 2003 Q4 | -103.79 Thousand USD | -15.93% |
| 2003 Q2 | -88.38 Thousand USD | 3.7% |
| 2003 Q1 | -91.77 Thousand USD | 36.83% |
| 2003 Q3 | -89.53 Thousand USD | -1.3% |
| 2002 Q1 | -126.21 Thousand USD | 5.0% |
| 2002 Q2 | -127.54 Thousand USD | -1.05% |
| 2002 Q3 | -4.5 Million USD | -3429.78% |
| 2002 Q4 | -145.28 Thousand USD | 96.77% |
| 2002 FY | -4.89 Million USD | -85102.0% |
| 2001 Q1 | -1500.00 USD | 60.0% |
| 2001 Q3 | -500.00 USD | 99.63% |
| 2001 Q2 | -135.82 Thousand USD | -8954.67% |
| 2001 FY | -5750.00 USD | 99.97% |
| 2001 Q4 | -132.86 Thousand USD | -26472.8% |
| 2000 Q4 | -3750.00 USD | 70.32% |
| 2000 Q2 | -21.47 Thousand USD | 99.88% |
| 2000 Q1 | -18.33 Million USD | -10954.86% |
| 2000 FY | -18.53 Million USD | -2169.85% |
| 2000 Q3 | -12.63 Thousand USD | 41.17% |
| 1999 FY | -816.59 Thousand USD | 82.27% |
| 1999 Q4 | -165.85 Thousand USD | 0.0% |
| 1998 Q3 | -1.3 Million USD | -154.36% |
| 1998 FY | -4.6 Million USD | 14.97% |
| 1998 Q1 | 4.2 Million USD | 4300.0% |
| 1998 Q2 | 2.4 Million USD | -42.86% |
| 1997 FY | -5.41 Million USD | -4.19% |
| 1997 Q4 | -100 Thousand USD | 90.22% |
| 1997 Q3 | -1.02 Million USD | -155.67% |
| 1997 Q2 | -400 Thousand USD | 20.0% |
| 1997 Q1 | -500 Thousand USD | 58.33% |
| 1996 FY | -5.19 Million USD | 18.75% |
| 1996 Q1 | 200 Thousand USD | 0.0% |
| 1996 Q2 | 200 Thousand USD | 0.0% |
| 1996 Q3 | -5.11 Million USD | -2658.54% |
| 1996 Q4 | -1.2 Million USD | 76.55% |
| 1995 Q4 | 200 Thousand USD | 0.0% |
| 1995 FY | -6.39 Million USD | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| America Great Health | -492.64 Thousand USD | 100.0% |
| Ampio Pharmaceuticals, Inc. | -9.51 Million USD | 100.0% |
| Aridis Pharmaceuticals, Inc. | -29.99 Million USD | 100.0% |
| Biora Therapeutics, Inc. | -67.14 Million USD | 100.0% |
| Bio-Path Holdings, Inc. | -15.84 Million USD | 100.0% |
| Better Therapeutics, Inc. | -38.26 Million USD | 100.0% |
| Calithera Biosciences, Inc. | -42.07 Million USD | 100.0% |
| Comera Life Sciences Holdings, Inc. | -11.97 Million USD | 100.0% |
| eFFECTOR Therapeutics, Inc. | -33.84 Million USD | 100.0% |
| Eloxx Pharmaceuticals, Inc. | -34.41 Million USD | 100.0% |
| Evelo Biosciences, Inc. | -108.46 Million USD | 100.0% |
| Evolutionary Genomics, Inc. | -2.01 Million USD | 100.0% |
| Finch Therapeutics Group, Inc. | -34 Million USD | 100.0% |
| Galera Therapeutics, Inc. | -46.95 Million USD | 100.0% |
| Innovation1 Biotech Inc. | -1.36 Million USD | 100.0% |
| Kiromic BioPharma, Inc. | -19.93 Million USD | 100.0% |
| Molecular Templates, Inc. | -10.46 Million USD | 100.0% |
| Navidea Biopharmaceuticals, Inc. | -14.05 Million USD | 100.0% |
| NexImmune, Inc. | -29.19 Million USD | 100.0% |
| Orgenesis Inc. | -53.63 Million USD | 100.0% |
| Panbela Therapeutics, Inc. | -51.29 Million USD | 100.0% |
| Point of Care Nano-Technology, Inc. | -78.01 Thousand USD | 100.0% |
| PaxMedica, Inc. Common Stock | -16.14 Million USD | 100.0% |
| Scopus BioPharma Inc. | -11.71 Million USD | 100.0% |
| Sorrento Therapeutics, Inc. | -504.31 Million USD | 100.0% |
| Statera Biopharma, Inc. | -98.34 Million USD | 100.0% |
| TRACON Pharmaceuticals, Inc. | -6.89 Million USD | 100.0% |
| Trevena, Inc. | -35.28 Million USD | 100.0% |
| Vaxxinity, Inc. | -58.28 Million USD | 100.0% |
| Vaccinex, Inc. | -22.88 Million USD | 100.0% |
| Vicapsys Life Sciences, Inc. | -1.04 Million USD | 100.0% |
| Viracta Therapeutics, Inc. | -50.69 Million USD | 100.0% |
| ZIVO Bioscience, Inc. | -7.26 Million USD | 100.0% |